Diagnosis and management of tumor-induced osteomalacia: a single center experience

[1]  P. Houillier,et al.  Challenges in the management of tumor-induced osteomalacia (TIO). , 2021, Bone.

[2]  R. Kumar,et al.  Burosumab for the Treatment of Tumor‐Induced Osteomalacia , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  Yutaka Takahashi,et al.  Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  W. Lv,et al.  Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  A. Folpe.  Phosphaturic mesenchymal tumors: A review and update. , 2019, Seminars in diagnostic pathology.

[6]  C. Faul,et al.  FGF23 Actions on Target Tissues—With and Without Klotho , 2018, Front. Endocrinol..

[7]  A. Molinolo,et al.  Tumor-induced osteomalacia , 2017, Bone reports.

[8]  Wei Yu,et al.  Reports of 17 Chinese patients with tumor-induced osteomalacia , 2017, Journal of Bone and Mineral Metabolism.

[9]  E. Kebebew,et al.  68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia. , 2016, The Journal of clinical endocrinology and metabolism.

[10]  K. White,et al.  Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice , 2016, PLoS biology.

[11]  R. Erben,et al.  FGF23 Regulates Bone Mineralization in a 1,25(OH)2D3 and Klotho‐Independent Manner , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  M. Collins,et al.  The PTH-Vitamin D-FGF23 axis , 2015, Reviews in Endocrine and Metabolic Disorders.

[13]  P. Hoffstetter,et al.  Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin , 2014, Case reports in endocrinology.

[14]  R. Recker,et al.  Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy. , 2013, The Journal of clinical endocrinology and metabolism.

[15]  A. Dwyer,et al.  Tumor localization and biochemical response to cure in tumor‐induced osteomalacia , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  A. Gill,et al.  Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. , 2013, The Journal of clinical endocrinology and metabolism.

[17]  J. Bilezikian,et al.  Tumor‐induced osteomalacia: An important cause of adult‐onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[19]  W. Richards,et al.  Fibroblast Growth Factor 23 (FGF23) and Alpha-Klotho Stimulate Osteoblastic MC3T3.E1 Cell Proliferation and Inhibit Mineralization , 2011, Calcified Tissue International.

[20]  M. Kuro-o,et al.  The Klotho gene family as a regulator of endocrine fibroblast growth factors , 2009, Molecular and Cellular Endocrinology.

[21]  R. Reilly,et al.  Hypophosphatemia: an evidence-based approach to its clinical consequences and management , 2006, Nature Clinical Practice Nephrology.

[22]  T. Yoneya,et al.  FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. , 2004, Biochemical and biophysical research communications.

[23]  E. Montgomery,et al.  Most Osteomalacia-associated Mesenchymal Tumors Are a Single Histopathologic Entity: An Analysis of 32 Cases and a Comprehensive Review of the Literature , 2004, The American journal of surgical pathology.

[24]  N. Watts,et al.  Localisation of mesenchymal tumours by somatostatin receptor imaging , 2002, The Lancet.

[25]  S. Takeda,et al.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Spector,et al.  The Autosomal Dominant Hypophosphatemic Rickets (ADHR) Gene Is a Secreted Polypeptide Overexpressed by Tumors that Cause Phosphate Wasting , 2001 .

[27]  O. Bijvoet,et al.  NOMOGRAM FOR DERIVATION OF RENAL THRESHOLD PHOSPHATE CONCENTRATION , 1975, The Lancet.